Christopher P. Cannon, MD, a professor of medicine at Harvard Medical School and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital, spoke about the benefit seen in a ...
SAN DIEGO — Discussing data on the investigational oral agent sotagliflozin — a first-in-class, oral dual inhibitor of both sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2) — for the ...
Sotagliflozin (Inpefa) had a 23% risk reduction for major adverse cardiovascular events in high-risk patients with type 2 diabetes and chronic kidney disease. The dual SGLT1/2 inhibitor yielded a 32% ...
The dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor sotagliflozin reduced major adverse cardiovascular events, with significant reductions in the individual outcomes of myocardial ...
After a rocky development and regulatory road, the FDA has approved sotagliflozin (Inpefa) for treating heart failure in patients with or without diabetes, manufacturer Lexicon Pharmaceuticals ...
Clinical trial data has shown that the drug helped 28.6% of patients achieve glycated hemoglobin of 7.0% of less by week 24 without severe hypoglycemia or diabetic ketoacidosis and also helped ...
The overall mean placebo-adjusted A1C reduction at week 24 was 0.37% in the 200mg dose arm (P Lexicon Pharmaceuticals announced more positive data from their Phase 3 trial of sotagliflozin, an ...
Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results